Author archives

Camelia DOBREA

Latest posts by Camelia DOBREA (see all)

    Articles signed on MÆDICA, JCM:

    Primary Hepatic Marginal Zone Lymphoma in a Patient with Chronic Hepatitis C

    SELECT ISSUE

    MÆDICA - a Journal of Clinical Medicine | Vol. 11, nr. 3, 2016
    ISSN 1841-9038  |  e-ISSN 2069-6116
    ISSN-L 1841-9038
    CNCSIS - CMR - B+

    HIGHLIGHTS

    Plagiatul – in actualitate

    Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]

    Committe on Publication Ethics

    A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

    Members Area


    Primary Hepatic Marginal Zone Lymphoma in a Patient with Chronic Hepatitis C

    , , , and

    ABSTRACT

    Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) is a low-grade malignant lymphoma that appears frequently in the stomach, but other sites can also be involved: the intestinal tract, lungs, head, neck, skin, thyroid, breasts and liver. Recently, epidemiological evidences support the idea that there is an association between hepatitis C and B-cell non-Hodgkin lymphomas (that include MALT as a subtype). Primary non-Hodgkin lymphomas confined only to the liver are very rare (only 0.016% of all cases of all non-Hodgkin’s lymphomas) and MALT is not the most frequent type.
    We present the case of a male patient, age 62, known with chronic hepatitis C, previously relapser after a 72 week treatment with peg-interferon alfa and ribavirin that was diagnosed at three years after the relapse with multiple focal liver lesions. One of the tumors was surgically removed and the histological exam performed demonstrated an extranodal marginal zone lymphoma with small B-cell with plasmacytoid differentiation confined only to the liver. Direct acting antiviral (DAA) therapy was started, but the virologic clearance was not obtained by week 10, leading to a change of DAA regimen at week 12. The antiviral therapy was continued until week 24. Imaging showed an increase in number and size of the focal lesions until week 12. At week 12 chemo- and immune-therapy was started with bendamustine and rituximab. Afterwards the evolution was favorable, the patient being now in complete remission and with undetectable viral load.
    Keywords: Liver lymphoma, C hepatitis, extranodal marginal zone lymphoma, liver tumor

    Full text | PDF

    2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications

    SELECT ISSUE

    MÆDICA - a Journal of Clinical Medicine | Vol. 11, nr. 1, 2016
    ISSN 1841-9038  |  e-ISSN 2069-6116
    ISSN-L 1841-9038
    CNCSIS - CMR - B+

    HIGHLIGHTS

    Plagiatul – in actualitate

    Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]

    Committe on Publication Ethics

    A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

    Members Area


    2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications

    , , , , , , , , , , , , , , , , , , , and

    ABSTRACT

    The 2016 WHO-CMP classification proposal defines a broad spectrum of JAK2 V617F mutated MPN phenotypes: normocellular ET, hypercellular ET due to increased erythropoiesis (prodromal PV), hypercellular ET with megakaryocytic-granulocytic myeloproliferation and splenomegaly (EMGM or masked PV), erythrocythemic PV, early and overt classical PV, advanced PV with MF and post-PV MF. ET heterozygous for the JAK2 V617F mutation is associated with low JAK2 mutation load and normal life expectance. PV patients are hetero-homozygous versus homozygous for the JAK2 V617F mutation in their early versus advanced stages with increasing JAK2 mutation load from less than 50% to 100% and increase of MPN disease burden during life long follow-up in terms of symptomatic splenomegaly, constitutional symptoms, bone marrow hypercellularity and secondary MF. Pretreatment bone marrow biopsy in prefibrotic MPNs is of diagnostic and prognostic importance. JAK2 exon 12 mutated MPN is a distinct benign early stage PV. CALR mutated hypercellular thrombocythemia show distinct PMGM bone marrow characteristics of clustered larged immature dysmorphic megakaryocytes with bulky (bulbous) hyperchromatic nuclei, which are not seen in JAK2 mutated ET and PV. MPL mutated normocellular thrombocythemia is featured by clustered giant megakaryocytes with hyperlobulated stag-horn-like nuclei without features of PV in blood and bone marrow. Myeloproliferative disease burden in each of the JAK2, CALR and MPL MPNs is best reflected by the degree of anemia, splenomegaly, mutation allele burden, bone marrow cellularity and myelofibrosis.

    Keywords: Myeloproliferative neoplasms; Essential thrombocythemia; Polycythemia vera; Primary megakaryocytic granulocytic myeloproliferation; Myelofibrosis; JAK2V617F mutation; MPL515 mutation; Calreticulin mutation; JAK2 wild type; Bone marrow pathology

    Full text | PDF

    Composite Diffuse Large B-Cell Lymphoma and Follicular B-Cell Lymphoma – Case Report and Review of Literature

    SELECT ISSUE

    MÆDICA - a Journal of Clinical Medicine | Vol. 9, nr. 2, 2014

    ISSN 1841-9038  |  e-ISSN 2069-6116
    ISSN-L 1841-9038
    CNCSIS - CMR - B+

    HIGHLIGHTS

    Plagiatul – in actualitate

    Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]

    Committe on Publication Ethics

    A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

    Members Area


    Composite Diffuse Large B-Cell Lymphoma and Follicular B-Cell Lymphoma – Case Report and Review of Literature

    , , , , , , , , , , and

    ABSTRACT

    Composite lymphoma refers to the co-occurrence of two or more morphologically and immunophenotypically separate lymphomas in the same topographic site at the time of clinical presentation. It is an infrequent type of lymphoid neoplasm, present in lymphoid tissue and may be due to the existence of two genetically related neoplasms such as transformation of a single lymphoma into another more aggressive lymphoma or be due to the presence of two clonally unrelated lymphomas. This paper is presenting a case of diffuse non-Hodgkin large B-cell lymphoma with areas of low grade and high grade follicular non-Hodgkin B-cell lymphoma in a retroperitoneal lymph node and spleen of an 62 year old woman. Histopathological examination and immunohistochemistry features proved the diagnosis of composite lymphoma.

    Full text | PDF